{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:48:29Z","timestamp":1793155709452,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P01CA265768"],"award-info":[{"award-number":["P01CA265768"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA211024"],"award-info":[{"award-number":["P50CA211024"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P01CA265768"],"award-info":[{"award-number":["P01CA265768"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH1410405"],"award-info":[{"award-number":["W81XWH1410405"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","award":["PCF-22CHAL05"],"award-info":[{"award-number":["PCF-22CHAL05"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","award":["25YOUN19"],"award-info":[{"award-number":["25YOUN19"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005410","name":"American-Italian Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005410","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["\u201cEzio, Maria e Bianca Panciera\u201d AIRC Fellowship for Abroad"],"award-info":[{"award-number":["\u201cEzio, Maria e Bianca Panciera\u201d AIRC Fellowship for Abroad"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["PF-24-1318851-01-MM"],"award-info":[{"award-number":["PF-24-1318851-01-MM"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Reprogrammed lipid metabolism with massive upregulation of tumor cell-autonomous synthesis of saturated fatty acids is a hallmark of prostate cancer (PCa) and is driven in part by aberrations in androgen receptor (AR) signaling. While lipid alterations are well described in primary PCa, the extent to which the circulating lipidome reflects tumor-associated metabolic changes in metastatic disease, and its role in therapy response, remains to be determined. This study aims to assess whether plasma lipid profiling captures tumor metabolic rewiring, and whether this reflects response to AR-targeting therapy, in metastatic castration-resistant PCa (mCRPC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Quantitative plasma lipidomics was performed on plasma samples collected from patients with mCRPC (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200950) and cancer-free subjects (C-FS,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200914). Samples from patients with mCRPC were collected longitudinally at the time of progression on androgen deprivation therapy prior to initiation of first-line enzalutamide (Enza), after the start of treatment with Enza, before progression on Enza.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared to C-FS, patients with mCRPC showed distinct lipidomic signatures, characterized by increased levels of monounsaturated lipids and altered composition of the phospholipid and sphingolipid pool, mimicking the aberrations known to occur in primary PCa tissue. Enza treatment markedly reduced total lipid levels, decreased major phospholipid classes and ceramides, while increasing sphingomyelins. Notably, quantitative differences in specific sphingolipid species occurring after Enza treatment correlated with survival outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Plasma lipidomics reflects key metabolic features of PCa and is profoundly impacted by AR inhibition, with prognostic relevance in patients with mCRPC. These findings support its potential as a non-invasive tool for monitoring disease activity and treatment response, and lay the groundwork for lipid-based biomarkers in mCRPC, while indicating that the lipidomic alterations observed may help inform ongoing and forthcoming research on metabolic targeting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41391-026-01100-z","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T02:46:14Z","timestamp":1773369974000},"page":"826-835","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Lipidomic profiling in metastatic prostate cancer captures tumor metabolic rewiring and its modulation by androgen receptor\u2013targeting therapy"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2704-1423","authenticated-orcid":false,"given":"Sara","family":"Bleve","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ravera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Pederzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Pakula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Brighi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5383-4469","authenticated-orcid":false,"given":"Emilio Francesco","family":"Giunta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9973-4869","authenticated-orcid":false,"given":"Giuseppe","family":"Schepisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Virga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Gurioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore Luca","family":"Burgio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7069-7980","authenticated-orcid":false,"given":"Giuseppe Nicolo\u2019","family":"Fanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2698-3220","authenticated-orcid":false,"given":"Lisa M.","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Nanus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7720-5077","authenticated-orcid":false,"given":"Johannes V.","family":"Swinnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5618-8079","authenticated-orcid":false,"given":"Pier Vitale","family":"Nuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0347-9179","authenticated-orcid":false,"given":"Cristian","family":"Lolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"De Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9674-8379","authenticated-orcid":false,"given":"Massimo","family":"Loda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"1100_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75:10\u201345.","journal-title":"CA Cancer J Clin"},{"key":"1100_CR2","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/s41391-021-00318-3","volume":"24","author":"ST Tagawa","year":"2021","unstructured":"Tagawa ST, Ramaswamy K, Huang A, Mardekian J, Schultz NM, Wang L, et al. Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate. Prostate Cancer Prostatic Dis. 2021;24:1032\u201340.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1100_CR3","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1200\/JCO-25-00007","volume":"43","author":"R Garje","year":"2025","unstructured":"Garje R, Riaz IB, Naqvi SAA, Rumble RB, Taplin ME, Kungel TM, et al. Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update. J Clin Oncol. 2025;43:2311\u201334.","journal-title":"J Clin Oncol"},{"key":"1100_CR4","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","volume":"86","author":"D Tilki","year":"2024","unstructured":"Tilki D, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. 2024;86:164\u201382.","journal-title":"Eur Urol"},{"key":"1100_CR5","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187\u201397.","journal-title":"N Engl J Med"},{"key":"1100_CR6","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"Beer","year":"2014","unstructured":"Beer, Armstrong TM, Rathkopf DE AJ, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424\u201333.","journal-title":"N Engl J Med"},{"key":"1100_CR7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1530\/ERC-13-0515","volume":"21","author":"SJ Barfeld","year":"2014","unstructured":"Barfeld SJ, Itkonen HM, Urbanucci A, Mills IG. Androgen-regulated metabolism and biosynthesis in prostate cancer. Endocr Relat Cancer. 2014;21:57\u201366.","journal-title":"Endocr Relat Cancer"},{"key":"1100_CR8","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/j.bbalip.2013.03.010","volume":"1831","author":"G Zadra","year":"2013","unstructured":"Zadra G, Photopoulos C, Loda M. The fat side of prostate cancer. Biochim Biophys Acta. 2013;1831:1518\u201332.","journal-title":"Biochim Biophys Acta"},{"key":"1100_CR9","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1530\/ERC-15-0556","volume":"23","author":"LM Butler","year":"2016","unstructured":"Butler LM, Centenera MM, Swinnen JV. Androgen control of lipid metabolism in prostate cancer: novel insights and future applications. Endocr Relat Cancer. 2016;23:219\u201327.","journal-title":"Endocr Relat Cancer"},{"key":"1100_CR10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.euo.2018.06.010","volume":"2","author":"F Giunchi","year":"2019","unstructured":"Giunchi F, Fiorentino M, Loda M. The Metabolic Landscape of Prostate Cancer. Eur Urol Oncol. 2019;2:28\u201336.","journal-title":"Eur Urol Oncol"},{"key":"1100_CR11","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1158\/1541-7786.MCR-24-0864","volume":"23","author":"S Flanagan","year":"2025","unstructured":"Flanagan S, Lis RT, Huang Y, Jehane L, Vaselkiv JB, Allott EH, et al. Tumor Cholesterol Synthesis, Statin Use, and Lethal Prostate Cancer. Mol Cancer Res. 2025;23:1025\u201333.","journal-title":"Mol Cancer Res"},{"key":"1100_CR12","doi-asserted-by":"publisher","first-page":"4981","DOI":"10.1158\/0008-5472.CAN-20-3863","volume":"81","author":"LM Butler","year":"2021","unstructured":"Butler LM, Mah CY, Machiels J, Vincent AD, Irani S, Mutuku SM, et al. Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition. Cancer Res. 2021;81:4981\u201393.","journal-title":"Cancer Res"},{"key":"1100_CR13","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1073\/pnas.1808834116","volume":"116","author":"G Zadra","year":"2019","unstructured":"Zadra G, Ribeiro CF, Chetta P, Ho Y, Cacciatore S, Gao X, et al. Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer. Proc Natl Acad Sci USA. 2019;116:631\u201340.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1100_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100797","volume":"34","author":"G Falchook","year":"2021","unstructured":"Falchook G, Infante J, Arkenau HT, Patel MR, Dean E, Borazanci E, et al. First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors. EClinicalMedicine. 2021;34:100797.","journal-title":"EClinicalMedicine"},{"key":"1100_CR15","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.adh1922","volume":"17","author":"CF Ribeiro","year":"2024","unstructured":"Ribeiro CF, Rodrigues S, Bastos DC, Fanelli GN, Pakula H, Foiani M, et al. Blocking lipid synthesis induces DNA damage in prostate cancer and increases cell death caused by PARP inhibition. Sci Signal. 2024;17:eadh1922.","journal-title":"Sci Signal"},{"key":"1100_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104910","volume":"214","author":"PV Nuzzo","year":"2025","unstructured":"Nuzzo PV, Rodrigues S, Ribeiro CF, Teixeira IF, Fanelli GN, Bleve S, et al. Targeting cancer metabolism: Therapeutic potential of the fatty acid synthase (FASN) inhibitors. Crit Rev Oncol Hematol. 2025;214:104910.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1100_CR17","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13046-023-02664-7","volume":"42","author":"A Talebi","year":"2023","unstructured":"Talebi A, de Laat V, Spotbeen X, Dehairs J, Rambow F, Rogiers A, et al. Pharmacological induction of membrane lipid poly-unsaturation sensitizes melanoma to ROS inducers and overcomes acquired resistance to targeted therapy. J Exp Clin Cancer Res. 2023;42:92.","journal-title":"J Exp Clin Cancer Res"},{"key":"1100_CR18","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015;373:737\u201346.","journal-title":"N Engl J Med"},{"key":"1100_CR19","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.ajur.2019.12.003","volume":"7","author":"CY Mah","year":"2020","unstructured":"Mah CY, Nassar ZD, Swinnen JV, Butler LM. Lipogenic effects of androgen signaling in normal and malignant prostate. Asian J Urol. 2020;7:258\u201370.","journal-title":"Asian J Urol"},{"key":"1100_CR20","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.annonc.2025.05.529","volume":"36","author":"HM Lin","year":"2025","unstructured":"Lin HM, Scheinberg T, Portman N, Kim RMN, Mellor R, Huynh K. al. Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post hoc analysis of the ENZAMET phase III randomised trial (ANZUP 1304). Ann Oncol. 2025;36:1068\u201377.","journal-title":"Ann Oncol"},{"key":"1100_CR21","doi-asserted-by":"publisher","first-page":"2400260","DOI":"10.1200\/PO.24.00260","volume":"8","author":"HM Lin","year":"2024","unstructured":"Lin HM, Yang X, Centenera MM, Huynh K, Giles C, Dehairs J, et al. Circulating Lipid Profiles Associated With Resistance to Androgen Deprivation Therapy in Localized Prostate Cancer. JCO Precision Oncology. 2024;8:2400260.","journal-title":"JCO Precision Oncology"},{"key":"1100_CR22","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1158\/0008-5472.CAN-20-2511","volume":"81","author":"MM Centenera","year":"2021","unstructured":"Centenera MM, Scott JS, Machiels J, Nassar ZD, Miller DC, Zinonos I, et al. ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer. Cancer Res. 2021;81:1704\u201318.","journal-title":"Cancer Res"},{"key":"1100_CR23","first-page":"358","volume":"9","author":"JV Swinnen","year":"2006","unstructured":"Swinnen JV, Brusselmans K, Verhoeven G. Increased lipogenesis in cancer cells: new players, novel targets. Curr Opin Clin Nutr Metab Care. 2006;9:358\u201365.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"1100_CR24","doi-asserted-by":"publisher","first-page":"a030569","DOI":"10.1101\/cshperspect.a030569","volume":"8","author":"G Zadra","year":"2018","unstructured":"Zadra G, Loda M. Metabolic Vulnerabilities of Prostate Cancer: Diagnostic and Therapeutic Opportunities. Cold Spring Harb Perspect Med. 2018;8:a030569.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"1100_CR25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/ijc.10127","volume":"98","author":"JV Swinnen","year":"2002","unstructured":"Swinnen JV, Roskams T, Joniau S, Van Poppel H, Oyen R, Baert L, et al. Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer. 2002;98:19\u201322.","journal-title":"Int J Cancer"},{"key":"1100_CR26","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/s41391-021-00338-z","volume":"24","author":"HM Lin","year":"2021","unstructured":"Lin HM, Huynh K, Kohli M, Tan W, Azad AA, Yeung N, et al. Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2021;24:860\u201370.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1100_CR27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nrc.2017.96","volume":"18","author":"B Ogretmen","year":"2018","unstructured":"Ogretmen B. Sphingolipid metabolism in cancer signalling and therapy. Nat Rev Cancer. 2018;18:33\u201350.","journal-title":"Nat Rev Cancer"},{"key":"1100_CR28","doi-asserted-by":"publisher","first-page":"8048","DOI":"10.1371\/journal.pone.0008048","volume":"4","author":"A Dayon","year":"2009","unstructured":"Dayon A, Brizuela L, Martin C, Mazerolles C, Pirot N, Doumerc N, et al. Sphingosine kinase-1 is central to androgen-regulated prostate cancer growth and survival. PLoS One. 2009;4:8048.","journal-title":"PLoS One"},{"key":"1100_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.106058","volume":"123","author":"N Portman","year":"2025","unstructured":"Portman N, Mak B, Yeung N, Lin HM, Kim RMN, Mellor R, et al. Characterising the effect of circulating sphingolipids on metastatic prostate cancer cells. EBioMedicine. 2025;123:106058.","journal-title":"EBioMedicine"},{"key":"1100_CR30","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1002\/ijc.30903","volume":"141","author":"HM Lin","year":"2017","unstructured":"Lin HM, Mahon KL, Weir JM, Mundra PA, Spielman C, Briscoe K, et al. A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancer. Int J Cancer. 2017;141:2112\u201320.","journal-title":"Int J Cancer"},{"key":"1100_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02298-0","volume":"20","author":"B Mak","year":"2022","unstructured":"Mak B, Lin HM, Kwan EM, Fettke H, Tran B, Davis ID, et al. Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer. BMC Med. 2022;20:112.","journal-title":"BMC Med"},{"key":"1100_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-44157-9","volume":"13","author":"C Cattrini","year":"2023","unstructured":"Cattrini C, Manfredi M, Barboro P, Ghirimoldi M, Mennitto A, Martini V, et al. Untargeted lipidomics reveal association of elevated plasma C18 ceramide levels with reduced survival in metastatic castration-resistant prostate cancer patients. Sci Rep. 2023;13:17791.","journal-title":"Sci Rep"},{"key":"1100_CR33","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.euo.2019.07.005","volume":"4","author":"Y Wang","year":"2021","unstructured":"Wang Y, Jacobs EJ, Carter BD, Gapstur SM, Stevens VL. Plasma Metabolomic Profiles and Risk of Advanced and Fatal Prostate Cancer. European Urology Oncology. 2021;4:56\u201365.","journal-title":"European Urology Oncology"},{"key":"1100_CR34","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41391-023-00666-2","volume":"27","author":"T Scheinberg","year":"2024","unstructured":"Scheinberg T, Lin HM, Fitzpatrick M, Azad AA, Bonnitcha P, Davies A, et al. PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2024;27:136\u201343.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1100_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17645-z","volume":"11","author":"J Vykoukal","year":"2020","unstructured":"Vykoukal J, Fahrmann JF, Gregg JR, Tang Z, Basourakos S, Irajizad E, et al. Caveolin-1-mediated sphingolipid oncometabolism underlies a metabolic vulnerability of prostate cancer. Nat Commun. 2020;11:4279.","journal-title":"Nat Commun"},{"key":"1100_CR36","doi-asserted-by":"publisher","first-page":"1595308","DOI":"10.1080\/23723556.2019.1595308","volume":"6","author":"G Zadra","year":"2019","unstructured":"Zadra G, Loda M. When fat goes down, prostate cancer is on the ropes. Mol Cell Oncol. 2019;6:1595308.","journal-title":"Mol Cell Oncol"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01100-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01100-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01100-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:00:16Z","timestamp":1790719216000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01100-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1100"],"URL":"https:\/\/doi.org\/10.1038\/s41391-026-01100-z","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"16 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The study was approved by the Institutional Review Board and Ethics Committee of IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori,\u201d Meldola, Italy (protocol code: IRST B073) and by the Weill Cornell Medicine Internal Review Board (IRB protocol number 0711009545) in New York City. The study was conducted in accordance with the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Conference of Harmonization.All patients provided informed consent for the collection, storage, analysis, and de- identified sharing of their data for research purposes.","order":2,"name":"Ethics","label":"Ethics statement","group":{"name":"EthicsHeading","label":"Ethics"}}]}}